Macomics

Macomics Ltd is an immuno-oncology and macrophage drug discovery company based in Edinburgh, UK, with additional facilities in Cambridge. Founded in 2020, the company specializes in precision medicines that modulate macrophage activity to treat cancer, neurological conditions, fibrotic diseases, and inflammatory disorders. Macomics was co-founded by experts in macrophage biology, Prof. Jeffrey Pollard and Dr. Luca Cassetta, and originated from research at the University of Edinburgh.

The company utilizes its proprietary ENIGMAC™ platform for genetic modeling of diseases and the development of therapeutics targeting disease-specific macrophages. Macomics is advancing a portfolio of therapeutics, including a lead asset targeting castration-resistant prostate cancer, which is nearing Investigational New Drug readiness. The company also offers drug discovery services and collaborates with partners like Ono Pharmaceutical Co., Ltd. to develop macrophage-targeting antibodies. Macomics is backed by investors such as Epidarex Capital and Scottish Enterprise, and actively participates in industry events.